ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

Proof of principle needed before launching “big science” program, advisors say.

March 11, 2005

FDA Revokes Avastin’s Accelerated Approval In Metastatic Breast Cancer Indication

November 18, 2011

NCI Unveils Checklist for Omics Studies

February 7, 2013

In Brief: Rosenthal Names ACS President; Brown, Lynch, Mintz Win ACS Medals of Honor

November 14, 1997

NIH Advisors Suggest Revamping Grant Application Review

June 14, 1996

House Encourages NCI To continue Leadership Role As Coordinator Of Cancer Program

October 8, 1999